NEOGAP Therapeutics AB is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund. We are located at Therapeutic Immune Design, Centre for Molecular Medicine at Karolinska Institute, Stockholm, Sweden.  Our vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system. Our mission is to become an important player in the battle against cancer by development and commercialisation of our innovative cancer immunotherapy.